Evidence map›Paper›PMID 41060448›Full record

ArticleSurgery today2026

Clinical utility of the cancer-inflammation prognostic index for identifying high-risk stage II colorectal cancer.

Masahisa Ohkuma, Teppei Kamada, Keisuke Goto, Shu Tsukihara, Yasunobu Kobayashi, Tadashi Abe, Yasuhiro Takano, Yuta Imaizumi, Shunjin Ryu, Yasuhiro Takeda and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masahisa OhkumaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Teppei KamadaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan. teppei0911show@yahoo.co.jp.
Keisuke GotoDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Shu TsukiharaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Yasunobu KobayashiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Tadashi AbeDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Yasuhiro TakanoDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Yuta ImaizumiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Shunjin RyuDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Yasuhiro TakedaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Makoto KosugeDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Ken EtoDepartment of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) is a major cause of cancer-related mortality. Current prognostic models rely primarily on tumor-specific features and may overlook host-tumor interactions. We conducted this study to assess the prognostic value of the cancer-inflammation prognostic index (CIPI), which combines carcinoembryonic antigen and neutrophil-to-lymphocyte ratio, in patients with stage II CRC.

methodsThe subjects of this retrospective study were 326 patients with pathologically confirmed stage II CRC who underwent curative resection at our hospital between 2008 and 2018. The optimal CIPI cutoff for predicting 5 year survival was established using receiver operating characteristic analysis. Patients were classified into High- and Low-CIPI groups, and survival outcomes were compared.

resultsMultivariate analysis identified a high CIPI (≥ 56.9) and inadequate lymph node dissection (≤ 12 nodes) as independent predictors of worse disease-free survival (DFS), and a high CIPI, older age, performance status ≥ 3, and limited lymph node dissection as independent predictors of worse overall survival (OS). Patients with a high-CIPI had significantly lower 5 year DFS and OS.

conclusionCIPI is a simple, objective preoperative biomarker independently associated with recurrence and survival in patients with stage II CRC and may enhance risk stratification for adjuvant therapy and postoperative surveillance.

Indexed as

Biomarkers, TumorCarcinoembryonic AntigenColorectal NeoplasmsInflammationAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansLymph Node ExcisionLymphocyte CountLymphocytesMaleMiddle AgedNeoplasm StagingBiomarkers, TumorCarcinoembryonic AntigenCancer-inflammation prognostic indexColorectal cancerHigh-risk stage ⅡSurvival

Identifiers

PMID41060448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.